National publications highlight UC stroke research
A number of national news publications highlighted research presented by the University of Cincinnati's Eva Mistry, MBBS, at the International Stroke Conference 2023.
Mistry presented the results of the BEST-II trial, which found using blood pressure medications to lower the top number of blood pressure readings (systolic blood pressure) may not be safe or effective among people who have an acute ischemic stroke and undergo a successful mechanical clot removal.
"This line of inquiry is probably not worth pursuing," Mistry, assistant professor in the Department of Neurology and Rehabilitation medicine in UC’s College of Medicine and a UC Health physician at the UC Gardner Neuroscience Institute, told Medscape. "If lowering blood pressure improves outcomes, that improvement is fairly marginal, and there are trends that suggest that, in fact, it might be harmful."
Read the Neurology Live article.
Read more about Mistry's research.
Featured photo at top of Dr. Mistry with a patient. Photo/Andrew Higley/UC Marketing + Brand.
Related Stories
The subtle changes in hearing you should never ignore
July 24, 2026
It’s easy to dismiss changes in hearing as minor. But as The Washington Post recently reported, these symptoms could also signal a medical emergency that many people don’t recognize — known as sudden sensorineural hearing loss, a rapid decline in hearing that occurs suddenly or over a few days.
UC experts say proper produce washing is key defense against Cyclospora
July 24, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
What are the options for male birth control?
July 24, 2026
Despite major advances in contraception during the past several decades, responsibility for pregnancy prevention falls largely on women. As recently reported in Endocrinology Advisor, a new generation of male contraceptive candidates is advancing into early- and mid-stage clinical trials.